Saudi Arabia's Pharma Market Is 'Open For Business'
This article was originally published in Scrip
Executive Summary
Saudi Arabia could be an exciting market for many pharmaceutical companies looking to grow their business. Not only is it the biggest market in the Gulf, worth $5.1bn in 2012, but it is also an important gateway for other markets in a region where demand is steadily growing. And now new developments at the Saudi Food & Drugs Authority (SFDA) means that firms will likely find it easier to get to the market, explains Hassaan Alwohaibi, director of product licensing at the SFDA's drug division.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.